Literature DB >> 2334433

Mode of inhibition of smooth muscle myosin light chain kinase by synthetic peptide analogs of the regulatory site.

M Ikebe1.   

Abstract

The functions associated with the inhibitory region and calmodulin binding region of smooth muscle myosin light chain kinase (MLCK) were studied using various synthetic peptide analogs. Peptides 480-501 and 483-498 strongly inhibited 61 kDa Ca2+/calmodulin-independent MLCK activity with Ki of 25 nM. Peptides 493-512 and 493-504 were considerably less effective as inhibitor of the Ca2+/calmodulin-independent MLCK and Kiapp. were 2 and 3 microM, respectively. Inhibition of Ca2+/calmodulin-independent MLCK by the peptides 480-501 and 483-498 were competitive with ATP and 20,000 dalton smooth muscle myosin light chain. The inhibition of native MLCK by peptide 493-512 was explained by the calmodulin depletion model in which the peptide binds to free calmodulin and prevents it from activating MLCK. On the other hand, the inhibition of native MLCK by the peptides 480-501 and 483-498 was explained by the binding of these peptides to the MLCK-calmodulin complex. The present study suggests that the inhibitory region of MLCK directly binds to MLCK active site and competes with both ATP and 20,000 dalton light chain so as to inhibit the enzyme.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2334433     DOI: 10.1016/0006-291x(90)92380-i

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Vascular smooth muscle contractile elements. Cellular regulation.

Authors:  J T Stull; P J Gallagher; B P Herring; K E Kamm
Journal:  Hypertension       Date:  1991-06       Impact factor: 10.190

2.  Affinity labelling of smooth-muscle myosin light-chain kinase with 5'-[p-(fluorosulphonyl)benzoyl]adenosine.

Authors:  H Komatsu; M Ikebe
Journal:  Biochem J       Date:  1993-11-15       Impact factor: 3.857

3.  Activation of smooth muscle myosin light chain kinase activity by a monoclonal antibody which recognizes the calmodulin-binding region.

Authors:  Y Araki; M Ikebe
Journal:  Biochem J       Date:  1991-05-01       Impact factor: 3.857

4.  Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro.

Authors:  Linda M Feighery; Sean W Cochrane; Teresa Quinn; Alan W Baird; Daniel O'Toole; Sian-Eleri Owens; Diarmuid O'Donoghue; Randall J Mrsny; David J Brayden
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

5.  Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293 cells.

Authors:  J Shi; S Takahashi; X-H Jin; Y-Q Li; Y Ito; Y Mori; R Inoue
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.